✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Nectar Lifesciences Ltd.

NECLIFE

Market Cap
₹498 Cr.
P/E
29.31

Nectar Lifesciences Ltd.

  • Nectar Lifesciences
  • SMS Lifesciences
  • Everest Organics
  • TJI Pharma - Small Cap
FAQs on Nectar Lifesciences Ltd. Shareprice

Nectar Lifesciences has given lower returns compared to its competitors.
Nectar Lifesciences has grown at ~-2.94% over the last 7yrs while peers have grown at a median rate of 12.35%

Nectar Lifesciences is not expensive.
Latest PE of Nectar Lifesciences is 29.31, while 3 year average PE is 39.09.
Also latest EV/EBITDA of Nectar Lifesciences is 6.29 while 3yr average is 12.4.

View FAQ's On Business
Growth Table
  • Nectar Lifesciences Ltd.
  • SMS Lifesciences
  • Everest Organics
Balance Sheet
  • Nectar Lifesciences Ltd.
  • SMS Lifesciences
  • Everest Organics
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Nectar Lifesciences Ltd.
  • SMS Lifesciences
  • Everest Organics
Cash Flow
  • Nectar Lifesciences Ltd.
  • SMS Lifesciences
  • Everest Organics
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Nectar Lifesciences Ltd.
  • SMS Lifesciences
  • Everest Organics
Quarterly Results
  • Nectar Lifesciences Ltd.
  • SMS Lifesciences
  • Everest Organics
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Nectar Lifesciences Ltd. Financials

Balance sheet of Nectar Lifesciences is moderately strong, But short term working capital might become an issue for this company.

Yes, The debt of Nectar Lifesciences is increasing.
Latest debt of Nectar Lifesciences is ₹611 Crs as of Sep-24.
This is greater than Mar-24 when it was ₹598 Crs.

Yes, profit is increasing.
The profit of Nectar Lifesciences is ₹17 Crs for TTM, ₹5 Crs for Mar 2024 and -₹24.18 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Nectar Lifesciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Inventory, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech